g**1
发帖数: 10330 | 1 辉瑞与美国政府签订32亿美元疫苗大单：每剂价格约为30.50美元
2022-06-30 06:15:26 来源: 科创板日报 上海 举报
6
分享至
财联社6月30日讯（编辑 牛占林）当地时间周三，辉瑞公司表示，已同美国政府签订新
的疫苗供应协议，美国政府将向辉瑞支付32亿美元，购买1.05亿剂新冠疫苗，预计最早
将于今年夏末交付。
该协议将为美国政府在今秋开展疫苗加强针行动提供保障，当前，由奥密克戎子变体BA
.4和BA.5引发的新一轮新冠感染潮，正在席卷美国。据美国疾病控制和预防中心周二数
据显示，上周由BA.4和BA.5导致的新增感染病例已经占到总感染的52%。
（来源：辉瑞官网）
美国食品药品监督管理局(FDA)的高级官员彼得·马克斯表示，新冠病毒的快速进化令
人不安，免疫力下降和出现新变种，增加了新冠大流行爆发的风险。
美国卫生与公众服务部表示，根据该协议，美国政府还拥有额外购买辉瑞和BioNTech公
司1.95亿剂新冠疫苗的选择权，使潜在疫苗供应量达到了3亿剂。
按照32亿美元的价格计算，每剂疫苗的平均价格约为30.50美元，而两年前辉瑞和政府
达成的初始协议为1亿剂，每剂疫苗的价格为19.50美元，相比之下，每剂疫苗的采购价
格上涨了50%以上。
美国卫生与公众服务部助理部长Dawn O'Connell表示：“我们期待着辉瑞疫苗的交付，
并将与州和地方卫生部门、药店、卫生保健提供者展开合作，在今年秋天为美国人民提
供这些疫苗。”
辉瑞公司首席执行官Albert Bourla表示：“这项新协议将有助于确保全国各地的人们
获得疫苗，并为他们提供保护，以应对当前和未来的新毒株。”
辉瑞上周发布声明称，针对奥密克戎开发的两款新冠疫苗在2/3期试验中的数据证明，
二者均引发了“高度免疫应答”。其中一款是针对奥密克戎的加强疫苗、另一款是针对
原始病毒和奥密克戎的二价疫苗。根据声明，与现有的新冠疫苗相比，二者在面对奥密
克戎BA.1变体时均能“大幅提高”免疫应答水平。同时，这两种候选疫苗的安全性和耐
受性都与原始疫苗相似。 | j******e
发帖数: 101 | | z*******e
发帖数: 1 | | h*****s
发帖数: 228 | | m*********9
发帖数: 56 | 5 将军们准备好打第4针啊？
其实下面这个还不错：
While NVAX with the most overlooked, most underappreciated news in the
entire COVID universe reported 82.5% protection at 6 months!
Imagine NVAX with potential 11.5% improvement switching to a bivalent that
would equate to 92% protection at 6 months! Vaccine buyers across the globe
I hope you're paying attention. Once again NVAX and GSK vaccines don't
belong in the same sentence.
Novavax Announces Extended Durability of Protection Against Infection and
Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
Feb 28, 2022
- NVX-CoV2373 demonstrates protection against symptomatic and asymptomatic
infection
- High level of vaccine efficacy maintained over a 6-month period of
surveillance
- Continued reassuring safety profile in line with previous trials
GAITHERSBURG, Md., Feb. 28, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX
), a biotechnology company dedicated to developing and commercializing next-
generation vaccines for serious infectious diseases, today shared extended
analysis from its pivotal Phase 3 clinical trial conducted in the United
Kingdom (UK), showing that a high level of efficacy for its protein-based
COVID-19 vaccine, NVX-CoV2373, was maintained over a 6-month period of
surveillance. Additionally, the analysis showed vaccine efficacy of 82.5% (
95% CI: 75.0, 87.7) in protection against all COVID-19 infection – both
symptomatic and asymptomatic – as measured by PCR+ or anti-N seroconversion.
"These data have two implications for NVX-CoV2373. Importantly, the vaccine
offers protection against symptomatic and asymptomatic COVID-19 infection
which may both interrupt virus transmission and prevent COVID-19 disease,"
said Gregory M. Glenn, M.D., President of Research and Development, Novavax.
"Additionally, we are encouraged to see that our COVID-19 vaccine maintains
a high level of durable efficacy and continues to exhibit a reassuring
safety profile in this extended timeframe."
The data build upon the final analysis of the UK Phase 3 trial, published in
the New England Journal of Medicine in June 2021, which was used as part of
Novavax' regulatory submissions for NVX-CoV2373 around the world and
demonstrated a vaccine efficacy of 89.7% (95% CI: 80.2, 94.6), with cases
collected over three months (median of 55 days of surveillance).
In the expanded data collection window, vaccine efficacy was evaluated over
a 6-month period from November 10, 2020, through May 10, 2021 (median of 101
days of surveillance). NVX-CoV2373 continued to show a reassuring safety
profile during this window, with adverse events that were balanced between
vaccine and placebo groups. Additionally, the trial demonstrated continued
protection with an overall vaccine efficacy of 82.7% (95% CI: 73.3, 88.8).
Vaccine efficacy against severe disease was 100% (95% CI: 17.9, 100) during
the 6-month efficacy collection window, in line with the initial analysis.
https://ir.novavax.com/2022-02-28-Novavax-Announces-Extended-Durability-of-
Protection-Against-Infection-and-Disease-in-United-Kingdom-COVID-19-Vaccine-
Phase-3-Clinical-Trial | I*3
发帖数: 7012 | 6 哥决定瘾会越来越大
【在 h*****s 的大作中提到】
: 以后每年至少一次加强针，直到永远。
| t*****9
发帖数: 10416 | 7 按弯弯之前的数据，打疫苗死的比得新冠 的要多哈 ～～～～～～～～～～～lol
当然躺平任艹 的数据要再研究
【在 h*****s 的大作中提到】
: 以后每年至少一次加强针，直到永远。
|
|
